Showing results (211-220 of 241) with videos related to

Sort By:
Pageof 25
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2011
Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14Kathleen I Pritchard, Lois E Shepherd, Judith-Anne W Chapman, et al.
Pharmacogenetics and Genomics|June 19, 2019
Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancerJames N Ingle, Krishna R Kalari, Yukihide Momozawa, et al.
Cancer|December 17, 2015
Cervical cancer control in Latin America: A call to actionBrittany L Bychkovsky, Mayra E Ferreyra, Kathrin Strasser-Weippl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2017
Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trialsR Yerushalmi, B Dong, J W Chapman, et al.
The Lancet. Oncology|December 14, 2012
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trialPaul E Goss, Ian E Smith, Joyce O'Shaughnessy, et al.
JCI Insight|July 24, 2020
Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole actionJunmei Cairns, James N Ingle, Tanda M Dudenkov, et al.
Journal of the National Cancer Institute|March 20, 2018
Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27Kathrin Strasser-Weippl, Michaela J Higgins, Judith-Anne W Chapman, et al.
Pharmacogenetics and Genomics|July 11, 2020
Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancerJames N Ingle, Krishna R Kalari, Poulami Barman, et al.
The New England Journal of Medicine|June 7, 2016
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 YearsPaul E Goss, James N Ingle, Kathleen I Pritchard, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2015
Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancerFrances M Boyle, Ian E Smith, Joyce O'Shaughnessy, et al.
Pageof 25